ArticleMolecular and cellular pediatrics2026
Untargeted metabolomics profiling of childhood asthma: linking metabolic pattern to disease severity.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma is a heterogeneous inflammatory airway disorder associated with complex metabolic alterations. Despite significant advances in diagnosis and treatment, its prevalence and disease burden continue to rise, particularly among children. Recent research reveals that metabolic alterations play a crucial role in the disease development, severity, and treatment response. This study aimed to investigate dysregulation of serum metabolites in children with moderate-to-severe asthma compared with healthy controls using an untargeted metabolomic profiling approach.
resultsHierarchical clustering and stratified analyses identified distinct metabolic signatures differentiating asthmatic patients from controls, with progressive changes reflecting increasing disease severity. Thirty-nine metabolites were found to be commonly dysregulated in moderate and severe asthma. Notably, adenosine and orotic acid were significantly upregulated, while 5-methoxytryptophol (5-MTX) was markedly downregulated, showing its lowest levels in severe asthma. Pathway enrichment analysis revealed significant disruptions in pyrimidine, amino acid, and urea cycle pathways.
conclusionsThe identified metabolites and disrupted metabolic pathways may offer potential biomarkers of disease severity and provide insights to guide future therapeutic strategies. However, their utility in clinical practice as diagnostic or prognostic biomarkers across the full spectrum of asthma requires further validation in independent cohorts that include children with mild disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.